To include your compound in the COVID-19 Resource Center, submit it here.

CymaBay raises $144M follow-on

Chronic liver disease company CymaBay Therapeutics Inc. (NASDAQ:CBAY) raised $144 million

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE